Revolutionizing Vitiligo Virtual Conference - December 2023 - Abstracts and Posters
500 - Patient-reported outcomes following 24 weeks of treatment with upadacitinib in adults with non-segmental vitiligo: results from a phase 2, randomized, double-blind, dose-ranging study
Khaled Ezzedine, Ahmed M Soliman, David Rosmarin, Amit G Pandya, Bethanee J Schlosser, Nanja van Geel
501 - Efficacy and safety of upadacitinib in a phase 2 randomized, double-blind, dose-ranging study of adults with extensive non-segmental vitiligo
Thierry Passeron, Khaled Ezzedine, Iltefat Hamzavi, Nanja van Geel, Bethanee J Schlosser, Xiaofei Hu, Xiaohong Huang, David Rosmarin, John E Harris, Heidi S Camp, Amit G Pandya
519 - Efficacy of prolonged ruxolitinib cream treatment for vitiligo among patients with limited or no initial response at 6 months
Albert Wolkerstorfer, Melinda J. Gooderham, Michael Sebastian, David Rosmarin, Andrew Blauvelt, Maryam Shayesteh Alam, Jacek Zdybski, Shaoceng Wei, Deanna Kornacki, Thierry Passeron, John E. Harris
536 - Association between Pediatric BMI and Vitiligo Distribution: An Observational Cohort Study
Ross O'Hagan, BA, Shira Wieder, MD, Marcel Perl, MD, Jonathan I. Silverberg, MD, PhD, MPH, and Nanette B. Silverberg, MD
537 - The distribution of thyroid disease by age in pediatric vitiligo
Nanette B. Silverberg, MD
543 - Early repigmentation of stable vitiligo through point-of-care melanocyte transfer using non-cultured autologous skin cell suspension
Munavalli, Girish
550 - Vitiligo is Associated with New onset Osteoporosis: A Population-based Study
Naama Tova Cohen, Nanette B. Silverberg, Khalaf Kridin MD, PhD
567 - Prognostic factors in pediatric patients with vitiligo
Martha Alejandra Morales-Sánchez, María Fernanda Villegas-Calzada, Graciela Astrid Acatitla-Acevedo, Nabil De Anda-Ortiz, Maria Luisa Peralta-Pedrero
571 - Case Series of Topical 1.5% Ruxolitinib Cream for Pediatric Vitiligo
Nanette Silverberg, MD, Harry M. Meister, and Mark Lebwohl MD
Results 1 - 9 of 9